Amneal Appoints Deborah M. Autor To Board of Directors

BRIDGEWATER, N.J.–(BUSINESS WIRE)–Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that Deborah M. Autor has been appointed to the Company’s Board of Directors, effective July 29, 2022.

Chirag and Chintu Patel, Co-Chief Executive Officers, stated, “Deb brings decades of global public and private expertise in the biopharmaceutical sector to our board at an important time of growth for Amneal. She has a proven track record of service and impact throughout her distinguished career in quality, regulatory, and policy. We are delighted to welcome Deb to the board and look forward to working closely with her as we execute our strategy and expand our business into new and more complex high growth areas.”

Most recently, Ms. Autor held global quality and regulatory leadership roles at AstraZeneca and Mylan N.V. From 2019 to 2021, Ms. Autor was Global Head of Regulatory Excellence at AstraZeneca, where she led regulatory operations, policy and intelligence for their submissions globally. Prior to that, Ms. Autor was at Mylan N.V. from 2013 to 2019, where she was Head of Strategic Global Quality and Regulatory Policy and Head of Global Quality. Prior to her leadership within the industry, she served at the U.S. Food and Drug Administration (“FDA”) for over a decade, including as Deputy Commissioner for Global Regulatory Operations and Policy where she oversaw all FDA inspections, criminal investigations and international operations for human and veterinary drugs, biologics, medical devices, tobacco and food. Before that, Ms. Autor served as Director of the Office of Compliance of the Center for Drug Evaluation and Research, leading enforcement and policymaking for compliance with all drug requirements, including, drug approval; current good manufacturing practices (GMP); human subject protection and bioresearch monitoring (GCP); import and export; and recalls. During her time at the FDA, she won several public service awards. Before joining the FDA, Ms. Autor was a Trial Attorney in the Office of Consumer Litigation of the U.S. Department of Justice, where she litigated civil and criminal cases on behalf of the FDA. She received a Juris Doctor, Magna Cum Laude, from Boston University School of Law and a Bachelor of Arts in Psychology from Columbia University, Barnard College. Ms. Autor also has diverse board experience, including currently serving as a Board Director for Pardes Biosciences, Inc. and Chair of Board for the FDA Alumni Association.

As a result of Ms. Autor’s appointment, the Amneal Board will comprise of eleven directors.

About Amneal

Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals, primarily within the United States. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across a broad range of complex products and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceutical products focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more, please visit www.amneal.com.